Skip to content
Study details
Enrolling now

Estrogen Supplementation and Bone Health in Women With CF

Johns Hopkins University
NCT IDNCT05704036ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

75

Study length

about 3.8 years

Ages

0–100

Sex

Female only

Locations

1 site in MD

What this study is about

Researchers are testing whether estrogen supplementation, including transdermal estrogen patches, affects bone health in women with cystic fibrosis. The trial also explores the feasibility of using transdermal estrogen and compares different forms of hormonal contraception on bone health. Participants will have their hormone levels, bone density, and quality of life assessed over time.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Progesterone
  • 2.Take Transdermal estrogen

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oraltransdermal

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

progesterone (Progestin hormone; prepares uterus lining), Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) (Estrogen Receptor Agonists)

Drug routes

oral (Oral Capsule), transdermal

Endpoints

Secondary: Change in quality of life as assessed by Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) questionnaire

Body systems

Respiratory